Vicore Pharma Holding (NASDAQ:VCRE) Stock Short Interest Falls 57.0%

Vicore Pharma Holding (NASDAQ:VCRE) saw a significant decline in short interest during the month of September. As of September 30th, there was short interest totaling 4,238 shares, a decline of 57.0% from the September 15th total of 9,857 shares. Based on an average trading volume of 39,075 shares, the days-to-cover ratio is currently 0.1 days.

Wall Street Analyst Weigh In

Several equities research analysts have recently weighed in on the stock. Jefferies Financial Group started coverage on shares of Vicore Pharma in a research note on Friday, October 9th. They issued a “buy” rating and a $25.00 target price on the stock. Weiss Ratings started coverage on Vicore Pharma in a research note on Thursday, October 8th. They set a “sell (e-)” rating for the company. One investment analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, Vicore Pharma currently has a consensus rating of “Hold” and a consensus target price of $25.00.

Vicore Pharma Stock Up 2.3%

NASDAQ:VCRE opened at $9.15 on Wednesday. Vicore Pharma has a 1-year low of $7.88 and a 1-year high of $17.80.

Vicore Pharma Company Profile

Vicore Pharma is a Swedish biopharmaceutical company focused on developing medicines for severe respiratory and pulmonary diseases. The company’s research is centered on treatments intended to address the underlying disease processes associated with conditions such as idiopathic pulmonary fibrosis and other forms of progressive lung fibrosis.

Vicore’s lead investigational program is buloxibutid, formerly known as C21, an orally administered small-molecule agonist of the angiotensin II type 2 receptor.